Clinical Trials Directory

Trials / Completed

CompletedNCT02336347

A Phase 1 Study Comparing AVP-786 With AVP-923

A Phase 1, Single-center, Randomized, Double-blind, Double-dummy, 2-way Crossover Study Comparing AVP-786 With AVP-923

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
62 (actual)
Sponsor
Avanir Pharmaceuticals · Industry
Sex
All
Age
18 Years – 60 Years
Healthy volunteers
Accepted

Summary

To compare pharmacokinetics (PK) of AVP-786 (deuterated \[d6\] dextromethorphan hydrobromide \[d6-DM\]/quinidine sulfate \[Q\]) to AVP-923 (dextromethorphan hydrobromide \[DM\]/Q) at steady state.

Conditions

Interventions

TypeNameDescription
DRUGAVP-786
DRUGAVP-923

Timeline

Start date
2014-05-01
Primary completion
2014-09-01
Completion
2015-03-01
First posted
2015-01-13
Last updated
2015-07-13

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT02336347. Inclusion in this directory is not an endorsement.